Xencor, Inc. (NASDAQ:XNCR) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Xencor, Inc. (NASDAQ:XNCR) have been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $28.00.

XNCR has been the topic of a number of recent analyst reports. William Blair initiated coverage on shares of Xencor in a report on Monday, April 21st. They issued an “outperform” rating on the stock. Barclays lowered their price target on shares of Xencor from $22.00 to $6.00 and set an “underweight” rating on the stock in a report on Thursday, May 8th. Wedbush restated an “outperform” rating and issued a $31.00 price target on shares of Xencor in a report on Wednesday, April 30th. Finally, Wall Street Zen cut shares of Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th.

Insider Activity at Xencor

In related news, EVP Nancy Valente sold 4,616 shares of Xencor stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $11.03, for a total value of $50,914.48. Following the completion of the sale, the executive vice president directly owned 49,169 shares in the company, valued at $542,334.07. This trade represents a 8.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Kurt A. Gustafson sold 2,993 shares of Xencor stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $9.22, for a total transaction of $27,595.46. Following the completion of the sale, the director owned 20,183 shares of the company’s stock, valued at $186,087.26. This trade represents a 12.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 15,810 shares of company stock valued at $154,123 over the last 90 days. Company insiders own 4.76% of the company’s stock.

Institutional Trading of Xencor

Several institutional investors and hedge funds have recently bought and sold shares of the business. Sterling Capital Management LLC lifted its stake in Xencor by 732.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 1,040 shares during the period. New York State Teachers Retirement System lifted its stake in Xencor by 2.1% during the 1st quarter. New York State Teachers Retirement System now owns 59,326 shares of the biopharmaceutical company’s stock valued at $631,000 after acquiring an additional 1,200 shares during the period. Summit Investment Advisors Inc. lifted its stake in Xencor by 22.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company’s stock valued at $162,000 after acquiring an additional 1,282 shares during the period. PNC Financial Services Group Inc. lifted its stake in Xencor by 49.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock valued at $93,000 after acquiring an additional 1,337 shares during the period. Finally, GF Fund Management CO. LTD. acquired a new stake in Xencor during the 4th quarter valued at approximately $34,000.

Xencor Trading Up 2.9%

NASDAQ XNCR opened at $8.30 on Thursday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.89 and a current ratio of 5.89. The company has a market capitalization of $590.71 million, a price-to-earnings ratio of -2.71 and a beta of 0.85. The company’s 50-day simple moving average is $8.80 and its two-hundred day simple moving average is $13.64. Xencor has a one year low of $7.16 and a one year high of $27.24.

Xencor (NASDAQ:XNCR) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.06). The business had revenue of $32.73 million for the quarter, compared to analysts’ expectations of $23.44 million. Xencor had a negative net margin of 181.17% and a negative return on equity of 31.94%. The company’s revenue for the quarter was up 104.6% on a year-over-year basis. During the same period last year, the business posted ($1.11) EPS. Equities analysts forecast that Xencor will post -3.68 EPS for the current fiscal year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.